'+
'| • '+heading+' |
| '+
''+
' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('| 4/26 - 6:59 AM \; \; | \n'); } if (allow) { document.write('CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb\'s Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma | \n'); } if (allow) { document.write('
| 4/25 - 6:59 AM \; \; | \n'); } if (allow) { document.write('Bristol Myers Squibb Reports First Quarter Financial Results for 2024 | \n'); } if (allow) { document.write('
| 4/25 - 5:22 AM \; \; | \n'); } if (allow) { document.write('PureTech Announces Annual Results for Year Ended December 31, 2023 | \n'); } if (allow) { document.write('
| 4/22 - 6:59 AM \; \; | \n'); } if (allow) { document.write('Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster | \n'); } if (allow) { document.write('
| 4/22 - 6:59 AM \; \; | \n'); } if (allow) { document.write('Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster | \n'); } if (allow) { document.write('
| 4/12 - 2:46 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY | \n'); } if (allow) { document.write('
| 4/11 - 9:11 AM \; \; | \n'); } if (allow) { document.write('Building a Better Future: Bristol Myers Squibb 2023 ESG Report | \n'); } if (allow) { document.write('
| 4/10 - 12:06 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY | \n'); } if (allow) { document.write('
| 4/8 - 11:30 AM \; \; | \n'); } if (allow) { document.write('KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) | \n'); } if (allow) { document.write('
| 4/8 - 7:06 AM \; \; | \n'); } if (allow) { document.write('Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals | \n'); } if (allow) { document.write('
| 4/6 - 1:15 PM \; \; | \n'); } if (allow) { document.write('Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society | \n'); } if (allow) { document.write('
| 4/6 - 1:15 PM \; \; | \n'); } if (allow) { document.write('Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society | \n'); } if (allow) { document.write('
| 4/5 - 9:05 AM \; \; | \n'); } if (allow) { document.write('U.S. FDA Approves Bristol Myers Squibb and 2seventy bio\'s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy | \n'); } if (allow) { document.write('
| 4/4 - 7:21 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY | \n'); } if (allow) { document.write('
| 4/2 - 8:08 PM \; \; | \n'); } if (allow) { document.write('European Commission Expands Approval of Bristol Myers Squibb\'s Reblozyl (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) | \n'); } if (allow) { document.write('
| 4/2 - 5:06 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY | \n'); } if (allow) { document.write('
| 4/2 - 2:31 PM \; \; | \n'); } if (allow) { document.write('Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals | \n'); } if (allow) { document.write('
| 4/2 - 6:59 AM \; \; | \n'); } if (allow) { document.write('Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals | \n'); } if (allow) { document.write('
| 4/1 - 7:30 AM \; \; | \n'); } if (allow) { document.write('Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic... | \n'); } if (allow) { document.write('
| 3/29 - 9:46 AM \; \; | \n'); } if (allow) { document.write('Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes | \n'); } if (allow) { document.write('
 | |
| more news | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' |
If you reached this page'+
' after attempting to place a TickerTech.com product onto your web page, go no further; you must sign up as a'+
' paying client. For pricing information please visit our products page, email '+
' services@tickertech.com, or give us a call at 1-866-515-2082.'+
' '+
'